Search | Clinical Trials Finder

Conditions: Healthy Volunteers, Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Interventions: ALN-PNP, Placebo (PB); Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 172 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2027
U.S. locations: 6
States / cities: Glendale, California • Los Angeles, California • Miami, Florida + 2 more

Conditions: Obesity, Insulin Resistance
Interventions: Weight loss with very low fat plant-based diet and regular exercise; Other
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 55 Years
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Large Cell Neuroendocrine Carcinoma, Large Cell Pulmonary Neuroendocrine Carcinoma of the Lung (LCNEC), Extrapulmonary Neuroendocrine Carcinoma (EP-NEC), Small Cell Lung Cancer (SCLC), Gastroenteropancreatic NEC (GEP NEC), NEC of the Bladder, Other DLL3 Expressing epNEC
Interventions: [212Pb]Pb-MP0712, [203Pb]Pb-MP0712; Drug · Other
Lead sponsor: Molecular Partners AG; Industry
Eligibility: 18 Years and older
Enrollment: 138 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 5
States / cities: Atlanta, Georgia • Glen Burnie, Maryland • Omaha, Nebraska + 2 more

Conditions: Sepsis-Induced Hypotension
Interventions: REGN7544, PB; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 16
States / cities: Tucson, Arizona • New Haven, Connecticut • Atlanta, Georgia + 10 more

Conditions: Triple Negative Breast Cancer, Blood and Image Guided, Optimization of Neoadjuvant Therapy, Phase 2
Interventions: Paclitaxel + Carboplatin, Pembrolizumab; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Plastic Bronchitis
Interventions: Not listed
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: Not listed
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Sleep Apnea, Obstructive
Interventions: Paced Breathing; Device
Lead sponsor: Philips Respironics; Industry
Eligibility: 21 Years to 70 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Type 2 Diabetes
Interventions: Plant-based diet with no oxysterols, Standard ADA Diet (SADA); Behavioral
Lead sponsor: Morehouse School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Burns, Wounds
Interventions: Kerlix AMD gauze; Other
Lead sponsor: Lucy A Wibbenmeyer; Other
Eligibility: 1 Year and older
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Healthy
Interventions: Supplement system + copaiba softgels, Supplement system + placebo softgels; Dietary Supplement
Lead sponsor: dōTERRA International; Industry
Eligibility: 30 Years to 55 Years
Enrollment: 97 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Pleasant Grove, Utah

Conditions: Autism Spectrum Disorder
Interventions: Sibling-mediated intervention; Behavioral
Lead sponsor: Arizona State University; Other
Eligibility: 5 Years to 11 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Round Rock, Texas

Conditions: HER2 Positive Breast Carcinoma, Stage IV Breast Cancer AJCC v6 and v7
Interventions: Comprehensive Geriatric Assessment, Laboratory Biomarker Analysis, Neratinib, Pharmacological Study; Other · Drug
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 60 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 7
States / cities: Corona, California • Duarte, California • Lancaster, California + 4 more

Conditions: Lead Exposure
Interventions: X-Ray Fluorescence Analyzer; Device
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years to 70 Years
Enrollment: 500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Breast Neoplasms, Peritoneal Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms
Interventions: ²¹²Pb-TCMC-Trastuzumab, trastuzumab; Other · Biological
Lead sponsor: Orano Med LLC; Industry
Eligibility: 19 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 2
States / cities: Birmingham, Alabama • San Diego, California

Conditions: Epilepsy, Partial
Interventions: Levetiracetam, Placebo (PB); Drug · Other
Lead sponsor: UCB Pharma; Industry
Eligibility: 4 Years to 16 Years
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 38
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 35 more

Conditions: Colorectal Carcinoma
Interventions: NPT-PLA, Usual Quality Improvement; Behavioral
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 45 Years to 75 Years
Enrollment: 2,200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
Interventions: azacitidine, sodium phenylbutyrate; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Acute Myeloid Leukemia
Interventions: Donor-Derived Ex-Vivo Expanded Natural Killer Cell Infusions; Drug
Lead sponsor: Michael Pulsipher; Other
Eligibility: 0 Years to 25 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 13
States / cities: Phoenix, Arizona • Los Angeles, California • Aurora, Colorado + 10 more

Conditions: Pancreatic Ductal Adenocarcinoma, Gastric Cancer, Esophageal Cancer, Colorectal Cancer, Ovarian Cancer, Head and Neck Cancer, Sarcoma, Mesothelioma
Interventions: [203Pb]Pb-PSV359, [212Pb]Pb-PSV359; Drug
Lead sponsor: Perspective Therapeutics; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 11
States / cities: Miami, Florida • Kansas City, Kansas • Lexington, Kentucky + 7 more

Conditions: Healthy Subjects
Interventions: Placebo, PB 718; Drug
Lead sponsor: PegBio Co., Ltd.; Other
Eligibility: 18 Years to 55 Years
Enrollment: 82 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Daytona Beach, Florida

Conditions: Autosomal Dominant Polycystic Kidney Disease, Nephrogenic Diabetes Insipidus, Acquired Nephrogenic Diabetes Insipidus, Congenital Nephrogenic Diabetes Insipidus
Interventions: PB; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Amyotrophic Lateral Sclerosis
Interventions: AMX0035; Drug
Lead sponsor: Amylyx Pharmaceuticals Inc.; Industry
Eligibility: 18 Years and older
U.S. locations: 20
States / cities: Los Angeles, California • Oakland, California • Fort Lauderdale, Florida + 14 more

Conditions: Cervical Cancer
Interventions: Nelfinavir, Cisplatin, Pelvic External Beam Radiation Therapy, Brachytherapy, Pharmacokinetic Sampling, Cervical Biopsy, Pelvic Examination, Pap Smear, Audiogram, Proctoscopy, Cytoscopy, Renal Ultrasound, CT Scan, Whole Body PET/CT Scan; Drug · Radiation · Procedure
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older · Female only
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Breast Cancer
Interventions: Not listed
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 317 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: New York, New York

Search by objective public record fields.

A Trial to Learn if ALN-PNP is Safe and Well Tolerated in Healthy Adults and Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

Effects of a Calorie Restricted, Very Low Fat Plant-based Diet and Multi-component Exercise Program on Metabolic Health

Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors

A Study of REGN7544 for the Treatment in Adult Patients With Sepsis-Induced Hypotension

Blood and imagE-guided Optimization of Neoadjuvant Therapy in People With Early Stage Triple-negative Breast cancER - the BETTER Trial

International Plastic Bronchitis Registry

Evaluation of an Algorithm to Detect Sleep and Wake in Continuous Positive Airway Pressure (CPAP)

Dietary Oxysterols and β-Cell Function Among African Americans

Kerlix Gauze Study in a Burn Trauma Unit and Its Effect on Healthcare Associated Infections in Burn Patients

Natural Product System and Lifestyle Modification

Sibling-Mediated Intervention on Literacy and Reciprocity for Children With Autism

Neratinib in Treating Older Patients With Stage IV HER2-Positive Breast Cancer

Bone-Lead Level Associations With Brain and Mental Health

Safety Study of ²¹²Pb-TCMC-Trastuzumab Radio Immunotherapy

A 19-week Cognition Study of Levetiracetam in Children With Partial Onset Seizures

Implementation of a ColoRectal Cancer Screening Tool in US Primary Care Practices - Usual Quality Improvement (10 Clinics) vs Normalization Process Theory-Participatory Learning in Action (10 Clinics)

Azacitidine Plus Phenylbutyrate in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome

Donor-Derived Ex-Vivo Expanded Natural Killer Cell Infusions in Children and Young Adults With High Risk Acute Myeloid Leukemia Receiving Myeloablative HLA-Haploidentical Hematopoietic Cell Transplant

Lead-212 PSV359 Therapy for Patients With Solid Tumors

A Phase 1, Double-blind, Randomized, Placebo-controlled, Single- and Multiple-dose Escalating Study

Probenecid (PB) to Treat Hereditary Nephrogenic Diabetes Insipidus (NDI), ADPKD Treated With Tolvaptan, and Severely Polyuric Patients With Previous Lithium Administration

An Intermediate Size Expanded Access Protocol of AMX0035 for ALS

Safety Study of Nelfinavir + Cisplatin + Pelvic Radiation Therapy to Treat Cervical Cancer

Treatment Patterns and Clinical Outcomes Among Patients With HR+/HER2- mBC Receiving Palbociclib Combination Therapy in the US Community Oncology Setting.